Durvalumab with fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer

Durvalumab in combination with chemotherapy is in clinical development for the treatment of resectable gastric cancer and gastro-oesophageal junction (GEJ) adenocarcinoma. Gastric cancers and GEJ adenocarcinoma are cancers that form in the inner lining of the stomach or where the stomach and the oesophagus meet. Risk factors of these cancers include obesity, older age, gastro-oesophageal reflux disease and long-term helicobacter pylori infection. Symptoms can include difficulty and pain when swallowing, nausea or vomiting, heartburn, indigestion, loss of appetite, fatigue, unexplained weight loss, or a lump in the upper abdomen. There is an unmet need to improve survival outcomes, as many patients who have been treated with surgery and chemotherapy often experience disease recurrence.